ERIONEX INC. sovereign mark — ERI ONE X

ERIONEX INC.

Therapeutic Intelligence

We are building the intelligence infrastructure layer powering global therapeutic innovation — for the next 50 years and beyond. A Canadian company. A planetary mission.

Mississauga, Ontario, Canada
Federal Corporation No. 1771030-5
Founded 2025

Who we are

A company built for a planetary mandate

ERIONEX INC. was founded on a single conviction: that the world’s most important industry — pharmaceutical development — is operating on infrastructure built for the last century. We are here to change that.

Our name encodes our purpose. ERI — the founder’s commitment. ONE — a unified global platform. X — therapeutic intelligence, the transformative force at the centre of everything we do.

We are not a software company that entered pharma. We are a pharmaceutical intelligence company that built the operating system making platforms compliant, sovereign, and interoperable across 15 global regulatory jurisdictions simultaneously. That distinction is everything.

How to think about ERIONEX INC.
Layer
What it is
ERIONEX INC.
The company — the founding entity, the mission, the people
ERIONEX OS
The operating system — what ERIONEX INC. builds and governs
HTaaS™
The category it created — Holistic Therapeutics-as-a-Service
The intelligence engine
The living semantic knowledge graph powering every therapeutic decision
The architecture
The multi-plane implementation layer — where the mission becomes executable
17+
Years of clinical therapeutic lifecycle experience at the founding
15
Global regulatory jurisdictions mapped into our platform architecture
500yr
Design horizon — we are building for the Planetary Therapeutic Memory

What we believe

The principles that govern everything we build

These are not marketing values. They are architectural decisions. Every architectural decision, every security layer, every line of code reflects them.

🇨🇦
Canada first
Health Canada is our primary regulatory authority. AWS ca-central-1 is our primary sovereign node. Canada is not our market — it is our foundation. Every jurisdiction we expand into is built on top of this Canadian bedrock.
🔒
Sovereign by design
Data sovereignty is not a compliance checkbox. It is a mathematical guarantee. We encode it into the architecture before any application is built, not after. Every patient record, every clinical dataset, every regulatory submission is protected at the foundational layer.
Compliant by architecture
Regulatory compliance is not a feature we add to our platform. It is the platform. Every workflow, every data element, every decision is governed in real time by the same regulatory logic that governs the pharmaceutical industry itself.
Built for permanence
We do not build for this quarter or this funding round. We build for the next 500 years. Every architectural decision is evaluated against the question: will this still be the right decision in 50 years? If the answer is no, we make a different decision.
🌍
Planetary in scope
A drug that takes 15 years to reach patients in Canada takes 20 years to reach patients in Brazil and 25 years in India. We consider that a solvable infrastructure problem. Our 15-jurisdiction architecture is not ambition — it is accountability.
🧬
Human at the core
Every data point, every clinical decision, every submission in our platform ultimately traces back to a patient. Every millisecond we save in drug development is a millisecond closer to a treatment reaching someone who needs it. We never lose sight of why any of this matters.

The founder

Built by someone who lived the problem

ERIONEX INC. was not founded by a software engineer who discovered pharma. It was founded by a pharmacist who spent 17 years inside the clinical therapeutic lifecycle and decided the infrastructure problem was too important to leave unsolved.

Eric Berko-Mensah
Founder & CEO  ·  ERIONEX INC.

Eric founded ERIONEX INC. from Mississauga, Ontario after 17 years working across the clinical therapeutic lifecycle — from pharmacy to clinical research to cloud architecture to AI. He saw firsthand how fragmented, sovereignty-blind, and AI-deficient pharmaceutical infrastructure was costing the industry trillions and costing patients years. He decided to build the operating system the industry did not know it needed.

His mandate is simple: discovery to post-marketing, in one sovereign, intelligent, compliant platform. No exceptions.

Pharmacy
MSc., MPharm — University of Wolverhampton, UK
Clinical Research
Postgraduate Diploma, Clinical Research · Pharmacovigilance · Regulatory Affairs — AAPS Toronto
Cloud
AWS Certified: Cloud Practitioner · Solutions Architect
AI / ML
Postgraduate Degree, Data Science · AI · ML — UT Austin, McCombs School of Business

Canada first

Why a Canadian company is uniquely positioned to solve this

Canada’s regulatory position, trade agreements, and sovereign infrastructure advantages make ERIONEX INC. not just a Canadian company — but a company that could only have been built in Canada.

🇨🇦
Health Canada primary
Health Canada is the most globally respected and internationally aligned regulatory authority for pharmaceutical submissions outside the US. A single Health Canada approval creates a cascade pathway across CPTPP’s 12-member markets.
📄
CPTPP trade advantage
Canada’s CPTPP membership gives ERIONEX INC. a 12-market regulatory cascade architecture unavailable to US-based competitors. A single filing in Canada can cascade to Australia, Japan, Singapore, Mexico, and seven other markets.
Sovereign infrastructure
AWS ca-central-1 is our primary node — Canada’s data sovereignty framework is the strongest in the G7 for health data. Canadian health data sovereignty is built into the platform’s architectural foundation, not added as a feature.
🤝
OIN & LOT membership
ERIONEX INC. holds dual membership in the Open Invention Network and LOT Network — secured March 2026 — alongside global technology leaders. This positions ERIONEX INC. as a peer, not a petitioner, in global technology governance.
🏛
Innovation ecosystem
IPON approved. CanExport eligible. ElevateIP eligible. NRC IRAP eligible. Canada’s innovation funding ecosystem provides ERIONEX INC. with non-dilutive capital pathways unavailable to comparable US startups.
🌎
G7 health leadership
Canada holds rotating G7 Health Track leadership positions that directly intersect with ERIONEX INC.’s ERIONEX Foundation mandate — the open governance body for Planetary Therapeutic Memory, currently in development.

Our journey

From idea to infrastructure

Every milestone below was earned through disciplined execution, not press releases. This is the institutional record of ERIONEX INC.’s first year.

2025 Q1
ERIONEX INC. incorporated
Federal Corporation No. 1771030-5 registered in Canada. The company was founded on a single conviction: the global pharmaceutical industry needed a new operating system, and Canada was the right place to build it.
2025 Q2–Q4
Master Specification completed — 5,045 pages
The ERIONEX OS Global Master Specification v5.2 was authored: 15 volumes, 144 chapters, 33 appendices, 5,045 pages. A fully documented multi-plane architecture with enterprise-grade security architecture, 6 patent families in filing, and a complete regulatory compliance framework across 15 jurisdictions.
2025 Q4
MVP completed — TRL 4 achieved
ERIONEX OS reached Technology Readiness Level 4 with MVP complete. The platform’s core architecture was validated in a laboratory environment against the full 5,045-page specification.
Mar 2026
OIN + LOT Network dual membership secured
ERIONEX INC. joined the Open Invention Network and LOT Network simultaneously in March 2026 — the dual membership that neutralises Google/IBM patent portfolios and blocks patent troll activity across 5,000+ member organisations.
Mar 2026
IPON approved
Innovative Patent Office Network approval granted, providing government-supported IP prosecution cost reduction for ERIONEX INC.’s six patent families in filing.
May 2026
Mark I sovereign brand confirmed
The ERIONEX INC. Sovereign Mark I — The Unified Sovereign — was formally confirmed as the official standalone brand mark. ERI · ONE · X encoded in geometry, colour, and structure. ERX-BRAND-001 v1.0 published.
Q3 2026
Provisional patents filing — in progress
Six provisional patent families in filing across US, EP, JP, CN, CA, KR, AU. 85+ claims covering the full platform architecture, sovereign data layer, intelligence aggregation, and real-world evidence planes.
June 2026
$14M seed round — actively raising
ERIONEX INC. is actively raising a $14,000,000 CAD seed round at an $85M pre-money valuation to fund the complete v5.2 architecture build. 24-month runway. Convertible note / SAFE. Qualified investor materials available under NDA.

Our platform

ERIONEX OS — the product that carries the mission

ERIONEX INC. has one product. One mandate. One platform. ERIONEX OS is the world’s first Unified Therapeutic Intelligence Operating System — built to govern the entire drug development lifecycle from a single sovereign intelligence layer.

ERIONEX OS

A multi-plane AI-native infrastructure platform spanning Discovery → Preclinical → Clinical → Regulatory → Manufacturing → Post-Market Surveillance. Sovereign by design. Compliant by architecture. Canadian at the core.

Multi-plane architecture Enterprise-grade security 15 jurisdictions 28 ISO standards HTaaS™ v5.2 TRL 4
Explore ERIONEX OS →

Get in touch

We welcome every conversation

Whether you are an investor, a potential pharma or CRO partner, a regulator, a journalist, or someone who wants to join the mission — we want to hear from you.

💰
Investors
We are raising a $14M seed round. Full investor materials — financial model, cap table, technical architecture, IP detail — are available under NDA to qualified investors.
info.erionex@gmail.com →
💊
Pharma & CRO Partners
If you are a pharmaceutical company or CRO interested in early platform access, a pilot programme, or a strategic partnership discussion, we would welcome the conversation.
info.erionex@gmail.com →
📰
Media & Press
Journalists, analysts, and researchers covering pharmaceutical AI, Canadian technology innovation, or sovereign health infrastructure are welcome to reach out for background information.
info.erionex@gmail.com →
🧠
Careers
We are building a team of exceptional engineers, clinical informaticists, regulatory scientists, and AI researchers. If you want to build something that matters, we want to hear from you.
info.erionex@gmail.com →
Eric Berko-Mensah
Founder & CEO  ·  ERIONEX INC.  ·  202-1900 North Sheridan Way, Mississauga, ON L5K 2R3